Merus NV’s stock climbed to a record high on Monday after Genmab said it would acquire the company in an $8 billion all-cash transaction, despite a broad wave of analyst downgrades. Shares of Merus ...

Biotech company Genmab announced Sept. 29 it entered into an agreement to acquire all shares of Merus. The all-cash transaction is worth approximately $8 billion. Genmab is an international ...

Genmab is continuing to build up its pipeline of wholly owned late-stage cancer assets, this time paying $8 billion for Netherlands-based Merus and its bispecific antibody. Analysts praised the ...

Genmab’s growth and pipeline diversification strategy is picking up another piece through the acquisition of Merus in an $8 billion deal focused on a late-stage drug candidate projected to become a ...

Genmab (GMAB) to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage ...

- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO ® Annual Meeting - Based on the Company’s current operating plan, ...

Merus N.V. (NASDAQ:MRUS), a biotechnology company specializing in innovative antibody-based therapies with a market capitalization of $2.75 billion, has garnered significant attention from analysts ...

Merus has reported a 79% 12-month survival rate in cancer patients on its bispecific antibody, cementing William Blair analysts' belief the candidate has a “best-in-disease profile.” The bispecific ...

Merus (NASDAQ:MRUS) is one of the most promising stocks according to Wall Street analysts. The 2025 Annual Meeting of the American Society of Clinical Oncology/ASCO, held in Chicago, the US, from May ...

- Based on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., ...